well thought-out post, Rainmaker.
Maybe I'll be known as a reformed trader after holding INSV, but i can't get totally away from the trader's mentality of momentum.
What would you say are the near-term (trader, remember?) momentum events ahead of INSV and or their partners. A big one I'm sure would be a name-brand CEO.
The combo product at another step forward would be good, but I wonder if the much smaller market for those products will be discounted by investors pretty quickly. It's for this reason partially that I wonder if a buyout now with the combo product still in the future but not yet discounted would be our best option instead another alliance
Agree that INSV lost institutional buyers/holders when they went to OTCBB
If I'm wrong, tell me, but it seems INSV is noticeably different from most biotech in that #1 they've already licensed an FDA-approved product and the threat of further share dilution is minimal--the caveat obviously would be if INSV decides to be an acquirer instead of being acquired--perish the thought for me.
thanks, rain
News 
Market Data 
Discover 
